The sequence of the latent membrane protein 1 (LMP-1) gene was analysed in Epstein-Barr virus (EBV) isolates from specific regions representing both type 1 and type 2 EBV. A predominant strain marked by an XhoI restriction enzyme polymorphism (REP) within the LMP-1 gene has been identified in type 1 EBV in nasopharyngeal carcinoma (NPC) from Southern China. This polymorphism was also present in type 2 EBV in NPC from Alaska. In this study, the sequence of the LMP-1 gene was determined in these samples representing type 1 and type 2 EBV and was compared with the prototype lymphoid strains. Consistent nucleotide variation in the amino terminus of LMP-1 was identified in strains marked by the XhoI REP. These changes were present in both EBV type 1 and type 2 strains. Three types of sequence variation were detected in the carboxy terminus of LMP-1. The LMP-1 sequences differed in the number of an 11 amino acid repeat element. In the prototype EBV type 1 (B95-8) sequence and in the type 1 Raji and type 2 HR-1 strains, the third repeat element contained an insertion of 5 amino acids that were also the first five unique amino acids after the last partial repeat element. The third variation was a deletion of amino acids 343 to 352 of the B95-8 LMP-1. This deletion was detected in the type 1 Chinese EBV strains, but was not detected in the type 2 Alaskan strains although the Chinese and Alaskan strains have nearly identical amino acid changes at the amino terminus. Numerous other amino acid changes were detected in the carboxy terminus which did not cosegregate with either EBV type, amino acid changes in the amino terminus, or specific geographic regions. These data indicate that EBV strains can be distinguished by sequence differences within LMP-1 and that unlike the divergence between type 1 and type 2 EBV in Epstein-Barr nuclear antigen sequences, different EBV types are nearly identical in LMP-1 sequence.
Introduction
The Epstein-Barr virus (EBV), a ubiquitous human herpesvirus, is consistently detected in endemic Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC), and post-transplant lymphoma (PTL) (Epstein et al., 1964; Nonoyama & Pagano, 1973; Raab-Traub et al., 1987) . Two types of EBV have been distinguished by sequence divergence within the Epstein-Barr nuclear antigens (EBNAs -2, -3A, -3B and -3C) (Rowe et al., 1989; Sample et al., 1990) . The EBNA-2 gene is essential for lymphocyte transformation and the sequence variation within the EBNA-2 gene has been shown to affect lymphocyte transformation, with enhanced efficiency of transformation by type 1 EBV Cohen et al., 1989) .
Genetic studies have revealed that the EBV latent membrane protein 1 (LMP-1) is also essential for the transformation of B lymphocytes in vitro (Kaye et al., 1993) . LMP-1 has profound effects on B lymphocytes: it alters the expression of cellular activation antigens, adhesion molecules, and the bcl2 oncogene (Wang et al., 1988; Birkenbach e t al., 1989; Henderson et al., 1991) . It is also the only EBV gene that has transforming properties in rodent fibroblasts and has been shown to induce hyperplasia and increase keratin expression when expressed in the epidermis of transgenic mice (Wang et al., 1985; Baichwal & Sugden, 1988; Wilson et al., 1990) . In addition, LMP-1 is frequently expressed in both NPC and PTL suggesting that it may contribute to the aetiological role of EBV in these diseases (Fahraeus et al., 1988; Young et al., 1988 Young et al., , 1989 Gilligan et al., 1990) .
Analyses of strain variation based on restriction enzyme polymorphisms (REPs) have identified a predominant strain in NPC from Southern China (Lung et al., 1990) . One of the polymorphisms was the loss of an XhoI REP within the LMP-1 gene. This polymorphism was also present in all NPC from Alaska and in some of the NPC samples from Caucasian Americans but was not present in samples of NPC from Mediterranean Europe and Africa (Abdel-Hamid et al., 1992) . Analysis of the EBV type in the NPC samples indicated that the 0001-2403 © 1994 SGM IV. E. Miller and others Chinese strain was EBV type 1 based on the EBNA-2 sequence divergence whereas the Alaskan samples were EBV type 2.
To evaluate sequence variation within LMP-1 and its possible contribution to disease state, the sequence of the LMP-1 gene was determined for these samples representing type 1 and type 2 EBV from NPC and were compared with prototype lymphoid strains (Baer et al., 1984; Hatfull et al., 1988) . Fragments spanning the amino and carboxy cytoplasmic domains of LMP-1 were PCR amplified and their sequences were determined either directly from asymmetric PCR products or clones.
These data indicate that EBV strains can be identified by sequence differences within LMP-1. In comparison with the prototype B95-8 strain, characteristic sequence changes in LMP-1 are frequently detected in type 1 and type 2 EBV strains present in NPC from specific endemic regions. Additionally, in the permissive infection (hairy leukoplakia of the tongue), recombination during replication produced variation in the number of small repeat elements within LMP-1. In contrast, in the malignancies associated with EBV, the number of repeat elements was homogeneous confirming the clonality of the EBV genome in NPC-and EBV-associated tumours.
Methods
Tumour samples and cell lines. B lymphoid cell lines including B95-8, Raji, W91, P3HR-1, AG876, Louckes and two lymphoblastoid cell lines (LCLs), SFC3 and SFC4 established in the laboratory, were maintained at 37 °C in RPMI 1640 medium containing 10% fetal calf serum supplemented with antibiotics. Virus strains from seventeen EBV-positive epithelial tumour samples from distinct geographical regions, two EBV-positive PTLs, one BL, and four EBV-positive oral hairy leukoplakia (HLP) samples, were analysed in this study. C10, C11, C13, DOL, LKP and CHSICH are NPC tumours obtained from Southern China or Malaysia. M1, BA, 37997 and N49 are NPC tumours from American Caucasians. C15, C17, C18, N10, N12 and L80 are NPC tumours obtained from around the Mediterranean Abdel-Hamid et al., 1992) . AL is an NPC obtained from Alaska and OT is a parotid tumour obtained from the same geographical region that developed in an Alaskan Eskimo. HE and T594 are PTL from America, whereas COOP is an American BL. HLP0, HLP1, HLP2, and HLP3 are examples of HLPs. CA and TW refer to previously published LMP-1 sequences obtained from NPC tumours in Southern China and Taiwan and are included for comparison (Hu et al., 1991 ; Chen et al., 1992) .
Tumour processing and isolation of genomic DNA. Tumours were processed as described previously (Raab-Traub et al., 1983) . Tumour specimens were pulverized in a microdismembrator and suspended in 4 M-guanidine isothiocyanate (GITC). For processing of lymphoid cell lines, the pulverization step was omitted and the cells were suspended directly in GITC. After centrifugation through a caesium chloride step gradient, the DNA fraction was dialysed to remove the caesium chloride and GITC then treated with proteinase K and phenol extracted.
DNA sequencing. The PCR was used to amplify DNA corresponding to various regions of the LMP-1 gene. Approximately 100 to 300 ng of genomic DNA was used in each reaction. Exon 1 of LMP-I was PCRamplified using primers (nucleotides 169130 to 169150 and 169550 to 169531 or 169597 to 169612 of the B95-8 sequence). Following a round of asymmetric amplification, PCR products were directly sequenced using the Sanger dideoxynucleotide chain termination method (Sequenase; USB) and electrophoresed through urea-formamide polyacrylamide gels. The cytoplasmic carboxy domain was PCR amplifed using primers spanning the carboxy-terminal cytoplasmic domain of LMP-1 (nucleotides 168756 to 168736 and 168183 to 168163 of the B95-8 sequence) restriction enzyme sites were also included in each primer to facilitate cloning. Following amplification, products were either directly sequenced by the asymmetric method described above (W91 and P3HR-1) or cut with appropriate restriction enzymes and cloned into pGEM vectors (Promega). Plasmid DNA from individual clones; C15 (5), M1 (3), Cll (1), AL (1), C13 (2), OT (2), HE (2) and C17 (2), was sequenced using the Sequenase method as described above (numbers in parentheses refer to the number of clones sequenced from each isolate). Clones isolated from a C15 cDNA library were sequenced to complete the analysis of the C15 LMP-1 gene (Gilligan et al., 1990) .
PCR analysis of 33 bp repeats and 3" deletion in LMP-1. Genomic DNA from tissue samples was amplified by PCR and products were electrophoresed through 10% polyacrylamide gels to separate small fragments. For analysis of the number of repeats in the isolates, primers spanning the repeated sequences were used in the PCR reaction (nucleotides 168594 to 168575 and 168397 to 168378 of the B95-8 sequence). In some cases the PCR products could not be directly visualized on polyacrylamide gels and were transferred electrophoreticaUy to Zeta-Probe membrane (Bio-Rad) probed with an internal oligonucleotide corresponding to one of the repeat elements and exposed to Kodak XAR film. For analysis of the deletion between amino acids 343 and 352 in the carboxy terminus, PCR amplification across the deletion was performed using primers that would distinguish between the presence or absence of sequences coding for amino acids 343 to 352 (nucleotides 168348 to 168328 and 168183 to 168163 of the B95-8 sequence).
Results
The structure of the LMP-1 protein is unique with very hydrophilic cytoplasmic amino and carboxy domains with six membrane-spanning domains (Fig. 1) . The structure of the protein suggests that the amino and carboxy domains may interact with cellular proteins and through these interactions could affect cellular growth. Sequence analysis of the Raji strain of EBV, compared with the B95-8 strain, identified the presence of clusters of non-conservative amino acid changes in the cytoplasmic carboxy domain of LMP-1 and showed that the amino acid changes in the amino-terminal and membrane-spanning regions of the LMP-1 gene were very conservative (Hatfull et al., 1988) .
To evaluate the specific sequence variation within LMP-1, the complete sequence of LMP-1 gene was determined in the prototype NPC tumour C15. In addition, the sequences of the amino and carboxy cytoplasmic domains were determined in examples of EBV-positive lymphoid and NPC tumours from endemic and non-endemic regions.
Many of the samples analysed in this study were previously characterized by REPs and EBV typing based on sequence divergence within the EBNA-2 gene (AbdelHamid et al., 1992) . The samples include NPCs from Southeast Asia containing type 1 EBV that had lost an XhoI site within the LMP-1 gene that was retained in the B95-8 EBV strain. NPC samples from Alaska contained type 2 EBV that had also lost the XhoI site whereas NPC from Mediterranean Africa contained type 1 EBV with a BamHI polymorphism within the EBNA-2 sequences but did retain the XhoI site within LMP-1.
Sequence analysis of the C15 LMP-1 gene
The complete sequence of the LMP-1 gene isolated from the nude mouse-passaged C15 tumour was determined and compared with the sequence from the prototype B95-8 strain (Fig. 2) (Baer et al., 1984; Gilligan et al., 1990) . The sequence analysis revealed that the LMP-1 gene from the type 1 C15 NPC tumour is 99 % identical at the nucleotide level and 97 % identical at the amino acid level to the LMP-1 gene isolated from type 1 B95-8 cell line. Of the 12 nucleotide changes found in the LMP-1 open reading frame, 10 resulted in amino acid changes. With the exception of a glutamine to glutamic acid change at amino acid 322 in the carboxy-terminal region, the amino acid changes were relatively conservative. Several sequence changes between the C15 and B95-8 isolates were detected in the long cytoplasmic carboxy region of LMP-1. The C15 LMP-1 gene had five copies of the 11 amino acid repeat compared to four in the B95-8 strain. A five amino acid insertion (HDPLP) in the third 11 amino acid repeat sequence in the B95-8 strain that disrupts the perfect repeat sequence was not present in the C15 sequence. A third difference in the carboxy region of the C15 gene is the deletion of 10 amino acids (a.a. 343 to 352) near the 3' end of LMP-1. In addition, amino acid 338 of the B95-8 sequence was changed from Leu to a Ser in the C15 isolate. Considering the potential significance of phosphorylation on serine residues in this region of LMP-1 this change may represent an altered phosphorylation site (Moorthy & Thorley-Lawson, 1993) . This overall identity between LMP-1 genes from different EBV isolates is in agreement with previously published reports of LMP-1 sequences and may reflect and 84 (Cys to Gly). Considering the transition from a hydrophilic to hydrophobic domain of LMP-1 in this region, these sequence changes could possibly affect the folding or orientation of the protein in the plasma membrane. Additional nucleotide changes in the amino-terminal region of Alaskan and Chinese isolates were detected at amino acids 3, 25 and 82 and resulted in conservative amino acid changes. Seven additional nucleotide changes were also detected in all isolates that had lost the XhoI site, but these did not result in a change of the amino acid sequence. This cluster of 14 nucleotide changes was detected in all virus isolates obtained from the Far East, suggesting the presence of a distinct strain of EBV in that geographical region.
Interestingly, the Alaskan isolates also contained the same cluster of mutations as the Chinese isolates in the amino-terminal region, although the isolates are clearly different strains, as the Alaskan isolates are type 2 EBV strains based on sequence divergence in the EBNA-2 gene. Furthermore, the Alaskan isolates contain several additional mutations in the amino-terminal region not detected in the type 1 EBV Chinese isolates. These data reveal that two seemingly different strains of EBV have evolved a similar cluster of mutations in the aminoterminal region of LMP-1.
Sequence variation in the carboxy-terminal region of LMP-1
Considerable sequence variation among different EBV isolates was also detected within the carboxy-terminal region of LMP-1 (Table 2) . However, in contrast to changes in the amino-terminal region of LMP-1 these changes were not consistently detected in isolates from a specific geographical region. Analysis of the Raji LMP-1 gene in comparison to the B95-8 variant revealed a striking cluster of amino acid changes in the carboxyterminal region of LMP-1. This clustering of changes suggested a selective pressure for mutation of the LMP-1 gene possibly to escape immune recognition of LMP-lexpressing cells (Hatfull et al., 1988) . The clusters of changes detected at amino acids 212 to 214 and 353 to 355 in LMP-1 from the Raji strain were not detected in any of the strains analysed in this study. A Gly to Ser change detected at amino acid 212 of the Raji sequence was detected in 11 of 13 isolates sequenced. Changes were also detected at amino acids 354 and 355 of the Alaskan isolates (AL and OT) which result in Gly to Asp and Gly to Val changes, respectively. Although consistent patterns of amino acid changes were not detected in the isolates sequenced in this study, the considerable variation could potentially contribute to the ability of EBV to avoid immune recognition of the LMP-1 protein.
Previous studies have demonstrated that LMP-1 is phosphorylated on serine 313 and threonine 324, and that LMP-1 may also be phosphorylated on serines 309 and 311 following phosphorylation of amino acid 313 (Moorthy & Thorley-Lawson, 1993 ). This finding suggested that phosphorylation of LMP-1 may modulate the function or maturation of the LMP-1 molecule. In this study mutations were detected in the sequence coding for amino acid 313 in three of 13 virus isolates, including the NPC and parotid carcinoma from Alaska (AL and OT) and a PTL (HE). These mutations would result in a change from Ser to Ala in the Alaskan tumours and Ser to Pro in the PTL. A mutation was also detected at serine 309 in 10 of 13 virus isolates (including AL and HE) resulting in a Ser to Asn amino acid change. The detection of virus isolates encoding LMP-1 proteins lacking serine 313 and which, therefore, cannot be phosphorylated, indicates that phosphorylation at these residues in the LMP-1 gene product is not critical to the potential function LMP-1 in EBV-associated malignancies such as PTL and NPC.
Identification of a deletion between amino acids 343 and 352
Sequence analysis of LMP-1 genes isolated from Chinese and Taiwanese NPC tumours identified a deletion of 10 amino acids (GGGHSHDSGH) in the cytoplasmic domain of LMP-1 (Hu et at., 1991 ; Chert et al.., 1992) . Analysis of the LMP-1 gene isolated from EBV-positive Hodgkin's tumours has also revealed the existence of deletions in the carboxy-terminal region of the gene (Knect et al., 1993) . A deletion corresponding to amino acids 343 to 352 of the B95-8 strain was also detected in the LMP-1 gene isolated from the prototype C15 NPC tumour. To determine whether this same deletion was consistently present in any of the geographical or disease variants, additional virus isolates were examined for the presence of this deletion by PCR analysis (Fig. 3) . The deletion was detected in 11 of 24 strains examined, and was detected in both type 1 and type 2 EBV strains and in strains isolated from the Far East, the Mediterranean and U.S.A. (Table 3) . Interestingly, amino acids 343 to 352 were deleted in all strains analysed from the Far East. This deletion was detected in all the type 1 Chinese strains, but was not present in the type 2 Alaskan strains even though the Chinese and Alaskan strains were nearly identical within the amino terminus of LMP-1. This difference further supports the conclusion that the Chinese and Alaskan isolates are clearly distinct strains despite similar amino acid changes in the amino-terminal region of LMP-1.
Variation in the 33 bp repeat element in LMP-1
Previous reports have demonstrated the presence of a varying number of an 11 amino acid repeat between amino acids 250 and 308 in the carboxy-terminal domain of LMP-1. The B95-8 and Raji strains both have four perfect repeats with a disruption of five amino acids in the middle of the third repeat (Fennewald et al., 1984;  There was no correlation between the n u m b e r o f repeat elements and disease state or geographical location. The only EBV isolate that contained an insertion disrupting the third repeat element o f LMP-1 other than B95-8 and Raji was the P3HR-1 isolate, which was derived from an African BL. P C R amplification o f D N A isolated from N P C samples or other latently infected tissues consistently yielded a single b a n d representing a single species of the LMP-1 gene. In contrast P C R amplification across the repeats in samples from the permissive infection H L P p r o d u c e d multiple bands representing L M P -1 genes with a different n u m b e r of repeat elements (Fig. 4) . To determine whether the variation in the n u m b e r o f repeat elements in L M P -1 resulted from co-infection with different EBV strains or was the result o f r e c o m b i n a t i o n across repeat elements during replication o f the virus, the entire c a r b o x y d o m a i n o f LMP-1 was cloned from the H L P 3 biopsy and the resultant clones were screened by P C R to determine the n u m b e r o f repeats present in each clone. P C R amplification using total D N A from the H L P 3 sample as a template yielded multiple bands (representing six, five, and four repeats), whereas P C R amplification of the individual cloned p l a s m i d D N A as a 4) contains a single band representing four, five, or six repeats in the carboxy-terminus of LMP-1. This is in contrast to the same amplification of genomic DNA, which yielded three bands. Sequence analysis of unique regions of LMP-1 indicates that the clones with different repeat number are derived from the same strain and suggests that the multiple bands in the total DNA sample arose by recombination during lytic replication.
template resulted in the amplification of a single band only, representing four, five, or six repeats (Fig. 5) . The DNA sequence of unique regions from the carboxy region of LMP-1 was determined from individual clones of the HLP3 sample. Sequence analysis revealed that all of the clones contained different numbers of repeat elements, yet were identical in the regions surrounding the repeated sequences. These data suggest that the heterogeneity in repeat numbers is due to recombination during permissive replication of EBV in HLP infections, in contrast to predominantly latent infections of EBV such as NPC. One NPC sample (AL) did yield multiple bands representing different numbers of the 11 amino acid repeat in LMP-1. Analysis of this sample by Southern blot revealed multiple terminal fragments suggesting replication of the virus in some cells (data not shown). Therefore the multiple repeat sequences in LMP-1 could be the result of recombination during replication. The presence of a single band in most of the latently infected samples further supports the observation that EBV-associated malignancies contain clonal EBV DNA and represent the clonal expansion of a single infected cell (Raab-Traub & Flynn, 1986 ).
Discussion
The EBV-encoded LMP-1 is essential for growth transformation of B lymphocytes in vitro, and is the only EBV-encoded protein able to transform rodent fibroblasts in culture (Wang et al., 1985; Baichwal & Sugden, 1988; Kaye et al., 1993) . Additionally the protein has been detected in at least 65 % of NPC tumours at the protein level (Young et al., 1988) . Most of the molecular studies using the protein to date have utilized the B95-8 isolate of the LMP-1 gene, and it is possible that variation in LMP-1 from wild-type isolates may alter the function of LMP-1 or affect the recognition of the protein by the immune system. Since LMP-1 is essential for the transformation of B lymphocytes in vitro, it is also likely to play an important role in the ability of EBV to induce tumours in vivo. Analysis of the variation in naturally occurring isolates may identify domains or amino acids that are critical for the transforming function of the protein and sequences that are variable because of selective pressure from the immune system.
The sequence of the LMP-1 gene present in the prototype NPC turnout C15 has been determined and analysed in this study. The sequence is 99 % identical at the nucleotide level and 97 % identical in amino acid level to the sequence from the B95-8 isolate. The most divergence detected in the LMP1 gene in this study was in an isolate from a lymphoma that developed in an American white male following heart transplantation (HE). The HE isolate contained multiple changes but was still 96 % identical at the nucleotide level to the B95-8 isolate. In agreement with analyses of LMP-1 genes isolated from other strains, there is a high degree of overall conservation (96 to 99% identical to B95-8) between different isolates of EBV.
The sequence analysis of type 2 LMP-1 genes (P3HR-1, BA, OT and AL) also demonstrated that the distinction between type 1 and type 2 EBV based on EBNA divergence does not correlate with divergence in LMP-1. LMP-1 genes isolated from both type 1 and type 2 isolates were equally similar to the B95-8 isolate. Sequence analysis of the AG876 LMP-1 gene confirms this finding and indicates that this LMP-1 gene from a type 2 EBV is also 99 % identical to the B95-8 strain (Sample et al., 1994) . The similarity in the LMP-1 genes from both type 1 and type 2 EBV isolates contrasts to the approximately 36 % divergence detected in the EBNA-2 gene from different isolates. This striking conservation between the LMP-1 genes from type 1 and type 2 EBV may be a result of functional constraints within the protein and reflects the importance of this gene in growth alteration and transformation of both B lymphocytes and epithelial cells.
Interestingly, the monoclonal antibody S12, which recognizes an epitope in the carboxy terminus of LMP-1, does not react with the LMP-1 protein expressed in the C15 tumour (Young et al., 1988) . A pool of monoclonal antibodies (CS1 to 4), which also recognizes epitopes within the carboxy terminus of LMP-1, does recognize the protein, confirming the presence of the protein in turnout extracts Young et al., 1988) . The C15 isolate does not contain any unique mutations in the carboxy terminus that would appear to disrupt the epitope for the S12 monoclonal antibody, but does contain sequence changes in the carboxy-terminal region including deletion of amino acids 343 to 352 and deletion of five amino acids in the third repeat. However, the Chinese isolate CAO also contains these changes and is recognized by the S12 monoclonal antibody, hence these changes alone are probably not responsible for the lack of recognition of the C15 LMP-1 protein by the S12 monoclonal antibody (Hu et al., 1991) . This suggests that subtle amino acid changes in the C t 5 sequence could interact with each other to disrupt the S12 epitope. Although LMP-1 was highly conserved, variation was detected in the carboxy-terminal cytoplasmic domain in all the isolates analysed in this study. This variation in the carboxy-terminal region of LMP-1 could affect recognition of LMP-1 by the available monoclonal antibodies, resulting in an underestimate of the proportion of NPC tumours expressing the LMP-1 protein.
Previous reports have identified a unique variant of EBV, marked by the loss of an XhoI site in the aminoterminal region of LMP-1, present in Southern China (Lung et al., 1990; Abdel-Hamid et al., 1992) . In this study the sequences of the amino-and carboxy-terminal regions have been analysed in several different virus isolates from different geographical regions as well as different disease states. In the anaino-terminal region the nucleotide sequences were on average 96 % identical to the B95-8 strains with a range in variation from the B95-8 sequence of 0.3% to 9%. Several non-conservative changes were detected in this region in all of the strains characterized by loss of the XhoI site. These alterations could affect the folding or positioning of LMP-1 in the cell membrane or could affect the ability of LMP-1 to interact with cellular proteins. Additionally, in contrast to the Chinese isolates, which are type 1 in EBNA sequences, the Alaskan isolates also contain the same sequence changes although they possess type 2 EBNA sequences and had distinct sequence alterations in the carboxy-terminal region of LMP-1. This finding suggests that two completely separate viral populations have evolved the same amino acid alterations.
The seemingly convergent evolution detected in this region of LMP-1 suggests that mutation of these amino acids imparts some advantage to the virus. Recent reports have demonstrated that the major cytotoxic T lymphocyte (CTL) response against EBV in individuals with the major histocompatibility complex (MHC) HLA-A11 haplotype is directed against residues 416 to 424 of EBNA-3B . Subsequent studies have shown that in a region of New Guinea in which the HLA-A11 haplotype is predominant, a strain of EBV has arisen that contains a point mutation in amino acid 424 of EBNA-3B. Processed peptides from EBNA-3B containing this mutation at residue-424 were unable to bind to MHC molecules and sensitize infected cells to CTL-mediated killing. Selective pressure possibly led to the production of this virus strain mutated in the EBNA-3B gene that could therefore avoid immune recognition and persist in these patients . NPC arises in several restricted populations, including Alaskan Eskimos and Cantonese from Southeastern China, these populations may have a predominance of a specific MHC haplotype. The prevalence of a specific MHC haplotype in these populations could provide a selection for viruses with these clusters of mutations in the amino-terminal region of LMP-1. The prevalence of such a haplotype in these populations may allow expression of LMP-1 in infected cells to go undetected by virtue of the inability of MHC molecules to properly process and present mutated LMP-1 peptides to circulating CTLs. Such a mechanism would allow the virus to resist immune recognition and may contribute to the prevalence of NPC tumours in these populations.
Alternatively, these clusters of mutations could affect the function of the LMP-1 gene. These mutations were detected primarily in epithelial-derived EBV-containing tumours from endemic geographical areas of the world. The cluster of mutations found in the amino-terminal portion of the gene may enable LMP-1 to interact with some as yet unknown protein specifically expressed in epithelial cells and thus may contribute to tissue-specific effects of EBV. Mechanisms such as evasion of the host immune response or altered function as a result of mutations in the LMP-1 gene in EBV from specific geographic areas or populations could contribute to the increased risk of these populations for EBV-associated malignancies.
Recent studies have revealed that LMP-1 becomes phosphorylated on Ser-313 and Thr-324 residues in the carboxy-terminal region ofLMP-1 (Moorthy & ThorleyLawson, 1993) . In vitro analysis has demonstrated that alteration of Ser-313 to Gly prevented detectable phosphorylation not only of residue 313, but also prevented phosphorylation of Thr-324. However, this mutation had no effect on the ability of LMP-1 to transform Rat-1 cells. Alteration of either Ser-313 or Thr-324 to residues with negative charges, which would appear constitutively phosphorylated, resulted in a protein which was either toxic (Ser-313 to Asp) or unable to transform Rat-1 cells . These experiments also demonstrated that preventing phosphorylation had no effect on the ability of LMP-1 to be cleaved, or on the release of the resulting p25 LMP-1 fragment into the cytoplasm (Moorthy & ThorleyLawson, 1993) . The evidence obtained in these studies on the phosphorylation of LMP-1 suggested that the active form of the molecule is the unphosphorylated form. In this study, mutations were detected which altered the Ser-313 residue. The mutations detected altered the serine to an alanine residue in two Alaskan tumours (AL and OT) and altered the serine to a proline in a PTL (HE). These mutations result in a LMP-1 molecule that would be unable to undergo phosphorylation. Thus mutation of serine 313 could increase the ability of LMP-1 to alter cellular growth properties, perhaps due to being in a constantly unphosphorylated activated state.
The LMP-1 gene contains a variable number of repeats of an 11 amino acid sequence in the carboxyterminal region. In this study the number of repeat elements in each isolate was analysed and found to vary between three and six copies, with no relationship between number of copies and either the geographical region or disease status of the infected patient. Previous analysis of the B95-8 and Raji isolates identified the presence of a five amino acid insert in the middle of the third repeat element (Baer et af., 1984; Hatfull et al., 1988) . Only one isolate analysed in this study, P3HR-1, contained this insert, indicating that disruption of the repeated sequence in LMP-1 is a relatively rare event. PCR amplification across the repeated sequence in LMP-1 consistently detected a single species in the EBVassociated tumours. In contrast, PCR amplification across the LMP-1 repeats from each of the HLP samples detected multiple bands representing LMP-1 genes with different numbers of repeated sequences. Sequence analysis of unique DNA in the carboxy domain of LMP-1 from HLP3 clones indicated that these samples contained the identical strain of EBV, and that the different number of repeats arose by recombination during lyric replication of EBV in these samples. These data therefore indicate that variation in repeat elements is not a valid marker of strain differences. However, the single band detected by PCR using primers spannittg the repeated sequence in LMP-1 from NPC and PTL samples supports the previous observation that these malignancies contain clonal EBV and are the result of clonal expansion of a single EBV-infected cell.
